Going beyond protocol is key for young people with cancer
For adolescents and young adults with cancer, individualised care that addresses their unique medical and psychosocial needs is essential to improving outcomes and quality of life
First-in-class p53 reactivator shows activity in advanced solid tumours
Initial results of a phase II trial with rezatapopt suggest real promise in an area that has eluded druggable targeting
Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
AI-powered three-dimensional tumour pathology
Computational models can overcome current limitations of 3D analysis of tumour samples
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
Ma: “We all need more than one mentor”
For Prof. Brigette Ma, dealing with diversity and finding opportunities in criticisms are essential to grow as oncology professionals
Artificial intelligence as a reliable research partner
Extensive research is focusing on the development of tools that may enhance drug development and personalised oncology in the near future
AI may be key to streamline patient allocation to clinical trials
As a proof of concept, an AI-powered large language model matching platform shows promise in patient selection
How AI is expediting clinical research: the use of synthetic real-world data
While synthetic real-world data may help overcome current challenges in clinical trials, it also introduces new complexities
Rethinking the limits of tissue-agnostic cancer therapy
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes